Skip to content
preclinicalImmune & Inflammation

Vilon

Also known as: Lys-Glu, KE dipeptide, Lysyl-Glutamic acid

Vilon (Lys-Glu) is a synthetic dipeptide bioregulator developed by Khavinson that targets immune and hematopoietic tissue. It is the simplest known immunomodulatory peptide — just two amino acids — and was derived from analysis of thymic peptide fractions. Preclinical studies report stimulation of bone marrow hematopoiesis, enhancement of colony-forming units, and restoration of immune function in aged animal models.

3 cited references·4 researched benefits

Quick Answer

Vilon (Lys-Glu) is a synthetic dipeptide bioregulator targeting immune and blood-forming tissue. As one of Khavinson's shortest bioactive peptides, it stimulates bone marrow hematopoiesis and enhances immune cell production. Preclinical studies show restoration of colony-forming units in irradiated and aged animal models. It represents the extreme of the bioregulation concept — tissue-specific gene regulation by a two-amino-acid peptide.

Key Facts

Mechanism
Vilon (Lys-Glu) is proposed to interact with specific DNA sequences in bone marrow and immune cell precursors, upregulating genes involved in hematopoiesis and lymphocyte differentiation. It reportedly stimulates colony-forming units for granulocytes, macrophages, and lymphocytes. The positively charged lysine residue may facilitate electrostatic interactions with negatively charged DNA. Research suggests it modulates cell proliferation through changes in chromatin structure and gene accessibility in hematopoietic stem cells.
Research Status
preclinical
Half-Life
~20–30 minutes
Molecular Formula
C₁₁H₂₁N₃O₅
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Hematopoietic stimulation — enhances bone marrow colony-forming units in preclinical modelspreliminary
  • Immune restoration — restores immune parameters in aged and immunosuppressed animal modelspreliminary
  • Minimal peptide — demonstrates that even dipeptides can have tissue-specific biological effectspreliminary
  • Safety profile — dipeptide composed of common amino acids with minimal toxicity concernsmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Oral or subcutaneous (research protocols)10–100 mcgDailyStudied primarily in preclinical animal models. No approved therapeutic dosing. Research protocols vary by study design.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Very few adverse effects reported in preclinical studiesrare

Frequently Asked Questions

Is Vilon clinically proven?
Vilon's evidence base is primarily preclinical (cell culture and animal studies) with limited human clinical data published in Russian journals. The dipeptide bioregulation concept is scientifically interesting but has not been validated through the large, randomized, placebo-controlled trials required by Western regulatory standards. It should be considered an experimental research compound rather than a proven therapeutic.
How does Vilon relate to other Khavinson peptides?
Vilon (Lys-Glu) is part of Khavinson's family of tissue-specific short peptides: Thymogen (Glu-Trp) for thymus, Epithalon (Ala-Glu-Asp-Gly) for pineal, Livagen (Lys-Glu-Asp-Ala) for liver, Cardiogen (Ala-Glu-Asp-Arg) for heart. Each is proposed to regulate gene expression in its target tissue. Vilon specifically targets bone marrow and immune progenitor cells.

References

  1. 1
    Effect of peptide Lys-Glu on hematopoiesis in irradiated and aging organisms(2004)
  2. 2
    Short peptides and their role in bioregulation of aging(2011)PubMed ↗
  3. 3
    Dipeptide bioregulators: structure-activity relationships and mechanisms of action(2014)PubMed ↗

Latest Research

Last updated: 2026-02-19